rs7852296 — DENND1A DENND1A PCOS Susceptibility Variant

An intronic variant in the DENND1A locus on chromosome 9q33.3, a robustly replicated PCOS susceptibility region; the A allele tags regulatory variation that drives DENND1A overexpression in theca cells, elevating androgen biosynthesis

See your personal result for DENND1A

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

DENND1A — When a Trafficking Protein Drives Hormone Excess

Deep inside ovarian theca cells, a protein better known for its role in cellular housekeeping has been implicated in one of the most common endocrine disorders in women of reproductive age. DENND1A11 DENND1A
DENN domain containing 1A; a guanine nucleotide exchange factor for RAB35 involved in clathrin-mediated endocytosis and receptor recycling sits at chromosome 9q33.3, a locus that genome-wide association studies have now replicated across multiple ethnicities as a polycystic ovary syndrome (PCOS) susceptibility region. The rs7852296 variant is an intronic tag SNP within this locus — the A allele marks a haplotype associated with elevated DENND1A expression in the tissues that produce androgens.

The Mechanism

DENND1A generates two splice variants. The canonical transcript (V1) participates in normal endosomal recycling. The shorter splice variant, DENND1A.V222 DENND1A.V2
the truncated isoform that retains the DENN domain but lacks the long C-terminal tail of V1; overexpressed in PCOS theca cells at both mRNA and protein level, accumulates selectively in PCOS-affected theca cells. When DENND1A.V2 is overexpressed experimentally in normal theca cells, CYP17A1 — the rate-limiting enzyme for androgen synthesis — is markedly upregulated, recapitulating the excess androgen production that characterises PCOS.

A complementary mechanism was identified in granulosa cells. Dou et al. 202433 Dou et al. 2024
DENND1A desensitizes granulosa cells to FSH by arresting intracellular FSHR transportation. Sci China Life Sci 67:1587–1600 demonstrated that elevated DENND1A expression disrupts the intracellular trafficking of the follicle-stimulating hormone receptor (FSHR), promoting its internalization while inhibiting recycling back to the cell surface. The net effect is FSH resistance — the granulosa cells cannot mount a normal response to the gonadotropin that drives follicle maturation. Transgenic mice overexpressing DENND1A showed reduced fertility, irregular cycles, and elevated testosterone, mirroring the human PCOS phenotype.

The causal chain from locus to disease was further anchored by a 2025 Nature Communications study: Sankaranarayanan et al. 202544 Sankaranarayanan et al. 2025
Gene regulatory activity associated with PCOS revealed DENND1A-dependent testosterone production. Nat Commun 16:7123 used STARR-seq to map regulatory elements within the DENND1A locus, identifying four variants with allele-specific activity that function as expression QTLs. CRISPR epigenome editing confirmed that activating these regulatory elements raises DENND1A expression and, downstream, testosterone production in adrenal cell models.

The Evidence

The DENND1A locus at 9q33.3 was first identified as a PCOS susceptibility region in Chinese cohorts and subsequently replicated in European populations. Goodarzi et al. 201255 Goodarzi et al. 2012
Replication of association of DENND1A and THADA variants with PCOS in European cohorts. J Med Genet 49:90–95 tested seven SNPs across LHCGR, THADA, and DENND1A in nearly 2,500 European PCOS cases and controls. The rs10818854-A allele showed the strongest DENND1A signal (combined OR 1.87, 95% CI 1.48–2.35, p=9.8×10⁻⁸; BMI-adjusted OR 2.02, p=6.5×10⁻⁸). The same paper noted that rs7852296, a neighbouring intronic variant in the same gene, had been associated with the personality dimension of Persistence in a genome-wide scan (p=9×10⁻⁶), illustrating that DENND1A regulatory variation influences diverse phenotypes across tissues.

A large European meta-analysis — Day et al. 201866 Day et al. 2018
Large-scale GWAS meta-analysis of PCOS suggests shared genetic architecture for different diagnosis criteria. PLoS Genet 14:e1007813 — combining 10,074 PCOS cases and 103,164 controls confirmed DENND1A as one of 14 replicated PCOS loci (rs9696009-A, beta 0.20, p=10⁻¹¹). Evidence that rare DENND1A noncoding variants contribute beyond common SNPs comes from whole-genome sequencing of PCOS families: Dapas et al. 202077 Dapas et al. 2020
Distinct subtypes of PCOS with novel genetic associations: an unsupervised, phenotypic clustering analysis. PLoS Med 17:e1003043 showed that carriers of rare DENND1A deleterious variants were significantly enriched in the reproductive PCOS subtype (high LH, normal BMI), underscoring that the locus exerts its effect primarily through the reproductive axis rather than the metabolic one.

The variant-level evidence for rs7852296 itself is sub-genome-wide-significant for PCOS (it appears in the GWAS Catalog as a DENND1A association with beta 0.17). Its clinical utility derives from its position as a tag SNP marking the broader DENND1A susceptibility haplotype, which has been replicated at genome-wide significance in multiple independent cohorts.

Practical Actions

Because the DENND1A mechanism is reproductive rather than metabolic, monitoring is most valuable in women with clinical signs of PCOS — irregular cycles, acne, excess hair growth, or difficulty conceiving. Elevated androgen levels (free testosterone, DHEAS) are the biomarker most directly connected to DENND1A pathway activity. Anti-Müllerian hormone (AMH) reflects the follicular arrest that FSH resistance produces, and elevated AMH is a hallmark of the reproductive PCOS subtype enriched for DENND1A variants.

Inositol supplementation — specifically myo-inositol and D-chiro-inositol — acts downstream of FSH signalling to improve ovarian sensitivity and has specific evidence in PCOS with FSH resistance. Spearmint tea has documented anti-androgenic activity in PCOS (reduces free testosterone via LH/FSH modulation) without systemic anti-androgen side effects.

Metformin and GLP-1 receptor agonists address the metabolic PCOS phenotype more than the reproductive one and are therefore less specifically targeted to the DENND1A pathway.

Interactions

The strongest known gene-gene interaction at the PCOS susceptibility level involves DENND1A together with THADA (rs13429458) and LHCGR (rs13405728). Each locus contributes independently to PCOS risk in European cohorts (Goodarzi 2012). Individuals carrying risk alleles at all three loci would represent the highest polygenic burden from this trio of loci, but no published compound effect size exists for the triple combination.

The reproductive PCOS subtype (enriched for DENND1A variants) overlaps with elevated LH pulsatility — making GNRH/LH axis variants (LHCGR rs13405728) the most biologically coherent interaction partner. The combined effect of impaired FSHR recycling (DENND1A) and altered LH receptor signalling (LHCGR) on follicular dynamics warrants investigation as a compound interaction.

Genotype Interpretations

What each possible genotype means for this variant.

GG Typical DENND1A Normal

Typical DENND1A locus — no elevated PCOS susceptibility from this variant

You carry two copies of the G allele at rs7852296, the most common genotype globally (approximately 79% of people). This genotype is not associated with elevated DENND1A expression in theca cells or increased PCOS susceptibility from this locus. About 90% of people of European descent share this or the AG genotype. Overall PCOS risk depends on many factors beyond this single locus.

AG One Risk Allele Intermediate

One copy of the DENND1A risk allele — modestly elevated PCOS susceptibility

The DENND1A locus on chromosome 9q33.3 has been replicated as a PCOS susceptibility region in multiple independent cohorts spanning Chinese and European ancestries. The lead variants in these studies (rs10818854, rs2479106, rs9696009) sit in the same locus as rs7852296, and all tag regulatory variation that drives elevated DENND1A.V2 expression. The DENND1A.V2 splice isoform upregulates CYP17A1 (the rate-limiting androgen synthesis enzyme) in theca cells and disrupts FSHR intracellular trafficking in granulosa cells.

Heterozygous carriers in European replication studies show intermediate frequencies in PCOS case–control comparisons (approximately 13.7% AG in PCOS cases vs 8.6% in controls for the closely linked rs10818854; Goodarzi 2012). The rs7852296-A allele itself shows a beta of 0.17 in the GWAS Catalog. Evidence level at this specific variant is moderate — the locus evidence is strong, but rs7852296 itself is a tag SNP rather than the functional variant.

AA Two Risk Alleles High Risk

Two copies of the DENND1A risk allele — elevated PCOS susceptibility from this locus

The DENND1A 9q33.3 locus was among the first PCOS susceptibility loci replicated across Chinese and European cohorts. The lead replication signal (rs10818854-A) showed OR 1.87 (95% CI 1.48–2.35) per risk allele in European PCOS case–control studies (Goodarzi 2012). Under additive scaling, the homozygous risk genotype approximately doubles the odds contributed by one copy. The biologically active mechanism is the DENND1A.V2 splice isoform selectively overexpressed in PCOS theca cells, which upregulates CYP17A1 and drives excess androgen production. Simultaneously, elevated DENND1A impairs FSHR recycling in granulosa cells, reducing FSH responsiveness and producing follicular arrest — the hallmark of polycystic ovarian morphology.

In whole-genome sequencing of PCOS families, rare deleterious DENND1A variants co-segregated with the reproductive PCOS subtype: elevated LH, elevated testosterone, but often normal BMI — a presentation that can be missed when clinicians anchor on obesity as a PCOS marker. The homozygous AA genotype at rs7852296, the rarest common-variant configuration at this locus, warrants proactive rather than reactive monitoring.